ClinicalTrials.Veeva

Menu

Effective OnabotulinumtoxinA Dose Response Study for Upper Facial Wrinkles

Northwell Health logo

Northwell Health

Status

Withdrawn

Conditions

Rhytides

Treatments

Drug: OnabotulinumtoxinA Standard Dose
Drug: OnabotulinumtoxinA Half Standard Dose

Study type

Interventional

Funder types

Other

Identifiers

NCT04994990
23-0015-NH

Details and patient eligibility

About

This research is being done to determine if lower doses of botox than what is currently recommended can give similar results to patients, at lower cost and lower risk to them. Subjects will receive botox in the same areas of the upper face with standard doses on one side of the face. On the other side, double the botox concentration will be administered, free of charge to the participant, in order to see if the difference in concentration creates a difference in wrinkle reduction and participant satisfaction over time.

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18-65
  • In good general health as evidenced by medical history and exhibiting upper facial wrinkles on physical examination
  • Agreement to adhere to Lifestyle Considerations (see section 5.3) as appropriate throughout study duration

Exclusion criteria

  • Current use of aminoglycosides, curare like agents, and muscle relaxants
  • Pregnancy or lactation
  • Known allergic reactions to components of the botox formulation and any of its ingredients
  • Treatment with another botox product for the face within 4 months
  • Infections/preexisting weakness at the proposed injection sites on physical examination
  • History of neuromuscular disorder, pre existing severe cardiovascular disease, compromised respiratory function, severe dysphagia
  • Pediatric population, patients older than 65 since the effect of botox in terms of duration and magnitude is highly variable in these age groups.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

0 participants in 2 patient groups

Standard Dosing Group
Active Comparator group
Treatment:
Drug: OnabotulinumtoxinA Standard Dose
Half Standard Dosing Group
Experimental group
Treatment:
Drug: OnabotulinumtoxinA Half Standard Dose

Trial contacts and locations

0

Loading...

Central trial contact

Nicholas Bastidas, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems